Carmine N. Stengone - Apr 4, 2024 Form 3 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
CEO and President, Director
Signature
/s/ Peter Slover, Attorney-in-Fact
Stock symbol
CTNM
Transactions as of
Apr 4, 2024
Transactions value $
$0
Form type
3
Date filed
4/4/2024, 05:49 PM
Previous filing
Oct 3, 2023
Next filing
May 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTNM Class A Common Stock 11.6K Apr 4, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTNM Stock Option (right to buy) Apr 4, 2024 Class A Common Stock 128K $1.26 Direct F1
holding CTNM Stock Option (right to buy) Apr 4, 2024 Class A Common Stock 289K $1.01 Direct F1
holding CTNM Stock Option (right to buy) Apr 4, 2024 Class A Common Stock 373K $8.45 Direct F2
holding CTNM Stock Option (right to buy) Apr 4, 2024 Class A Common Stock 179K $10.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.
F2 Options granted under the Plan. 25% of the options vest on March 11, 2022 and an additional 1/48th of the options vest monthly thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
F3 Options granted under the Plan. 25% of the options vest on September 27, 2024 and an additional 1/48th of the options vest monthly thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney